405 related articles for article (PubMed ID: 32098513)
1. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
[No Abstract] [Full Text] [Related]
2. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
Holcomb ZE; Porter ML; Kimball AB
Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
[TBL] [Abstract][Full Text] [Related]
3. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of hidradenitis suppurativa.
Folkes AS; Hawatmeh FZ; Wong A; Kerdel FA
Expert Opin Emerg Drugs; 2020 Sep; 25(3):201-211. PubMed ID: 32667213
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab: A Review in Hidradenitis Suppurativa.
Kim ES; Garnock-Jones KP; Keam SJ
Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
8. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
10. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
11. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
12. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
[No Abstract] [Full Text] [Related]
13. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
Nader A; Beck D; Noertersheuser P; Williams D; Mostafa N
Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.
Stergianou D; Kanni T; Damoulari C; Giamarellos-Bourboulis EJ
Expert Opin Biol Ther; 2024 Apr; 24(4):225-232. PubMed ID: 38602836
[TBL] [Abstract][Full Text] [Related]
15. Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab.
Stergianou D; Tzanetakou V; Argyropoulou M; Kanni T; Bagos PG; Giamarellos-Bourboulis EJ
Dermatology; 2021; 237(3):372-377. PubMed ID: 33401280
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
Zouboulis CC
Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapies for the treatment of hidradenitis suppurativa.
Rosales Santillan M; Morss PC; Porter ML; Kimball AB
Expert Opin Biol Ther; 2020 Jun; 20(6):621-633. PubMed ID: 32077334
[No Abstract] [Full Text] [Related]
18. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan.
Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
J Dermatol; 2023 Aug; 50(8):1034-1044. PubMed ID: 37264993
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with hidradenitis suppurativa.
Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
[TBL] [Abstract][Full Text] [Related]
20. Hidradenitis suppurativa managed with adalimumab.
Yamauchi PS; Mau N
J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]